Search

Your search keyword '"Antonioli, Elisabetta"' showing total 372 results

Search Constraints

Start Over You searched for: Author "Antonioli, Elisabetta" Remove constraint Author: "Antonioli, Elisabetta"
372 results on '"Antonioli, Elisabetta"'

Search Results

1. Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation

2. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study

5. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

7. Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy.

8. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

9. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

10. P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE

11. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network

14. MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

15. MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

16. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

17. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

18. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

19. Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study

20. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

21. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

22. Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)

26. The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

30. Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study

31. Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation

32. Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

33. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

34. Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

35. Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

37. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey

39. P-109 Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial

40. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis

41. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

42. Ventricular tachyarrhythmias and sudden cardiac death in light‐chain amyloidosis: a clash of cardio‐toxicities?

44. Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study

45. Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study

47. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients

48. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia

49. Minimal Residual Disease (MRD) at 10-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication)

50. A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma

Catalog

Books, media, physical & digital resources